{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:33:02Z","timestamp":1794573182886,"version":"4.9.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,31]]},"abstract":"<jats:p>Human herpes virus 8 (HHV-8) or Kaposi sarcoma-associated herpes virus is the etiologic agent of Kaposi sarcoma, primary effusion lymphoma, and plasma cell-type multicentric Castleman disease (MCD). HHV-8 encodes a viral homolog of human IL-6, called viral IL-6 (vIL-6), which does not require the cellular IL-6 receptor for binding to the ubiquitously expressed gp130 receptor subunit and subsequent JAK-STAT signaling. Thus, in contrast to IL-6, vIL-6 can stimulate virtually all cells in the body. To elucidate the mechanism by which vIL-6 drives human diseases, we generated transgenic mice that constitutively express vIL-6 under control of the MHC class I promoter. The mice were found to exhibit vIL-6 serum levels comparable with those observed in HHV-8\u2013infected patients, to contain elevated amounts of phosphorylated STAT3 in spleen and lymph nodes, where vIL-6 was produced, and to spontaneously develop key features of human plasma cell-type MCD, including splenomegaly, multifocal lymphadenopathy, hypergammaglobulin-emia, and plasmacytosis. Transfer of the vIL-6 transgene onto an IL-6\u2013deficient genetic background abrogated MCD-like phenotypes, indicating that endogenous mouse IL-6 is a crucial cofactor in the natural history of the disease. Our results in mice suggest that human IL-6 plays an important role in the pathogenesis of HHV-8\u2013associated MCD.<\/jats:p>","DOI":"10.1182\/blood-2011-09-377705","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T00:26:17Z","timestamp":1334017577000},"page":"5173-5181","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":117,"title":["HHV-8\u2013encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice"],"prefix":"10.1182","volume":"119","author":[{"given":"Jan","family":"Suthaus","sequence":"first","affiliation":[{"name":"Institute of Biochemistry, Christian-Albrechts-University, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Stuhlmann-Laeisz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Christian-Albrechts-University, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van S.","family":"Tompkins","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Rosean","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA;"},{"name":"Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Christian-Albrechts-University, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Tosato","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Janz","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA;"},{"name":"Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Scheller","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich-Heine-University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rose-John","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry, Christian-Albrechts-University, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5192","key":"2019111814452454000_B1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"issue":"5","key":"2019111814452454000_B2","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/JVI.73.5.4181-4187.1999","article-title":"Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.","volume":"73","author":"Staskus","year":"1999","journal-title":"J Virol"},{"key":"2019111814452454000_B3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-0-387-46816-7_3","article-title":"Molecular biology of KSHV in relation to AIDS-associated oncogenesis.","volume":"133","author":"Greene","year":"2007","journal-title":"Cancer Treat Res"},{"issue":"10","key":"2019111814452454000_B4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrc2888","article-title":"Kaposi's sarcoma and its associated herpesvirus.","volume":"10","author":"Mesri","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2019111814452454000_B5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/ng1384","article-title":"Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma.","volume":"36","author":"Wang","year":"2004","journal-title":"Nat Genet"},{"issue":"3","key":"2019111814452454000_B6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ccr.2007.01.015","article-title":"In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma.","volume":"11","author":"Mutlu","year":"2007","journal-title":"Cancer Cell"},{"issue":"18","key":"2019111814452454000_B7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111814452454000_B8","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.","volume":"86","author":"Soulier","year":"1995","journal-title":"Blood"},{"issue":"3","key":"2019111814452454000_B9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2559.2005.02319.x","article-title":"Immunoglobulin and T-cell receptor gene rearrangement in Castleman's disease: molecular genetic analysis.","volume":"48","author":"Al-Maghrabi","year":"2006","journal-title":"Histopathology"},{"issue":"11","key":"2019111814452454000_B10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1089\/jir.2011.0043","article-title":"Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus-associated malignancies.","volume":"31","author":"Sakakibara","year":"2011","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"2019111814452454000_B11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.191.3.445","article-title":"Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma.","volume":"191","author":"Yang","year":"2000","journal-title":"J Exp Med"},{"issue":"4","key":"2019111814452454000_B12","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1128\/JVI.77.4.2631-2639.2003","article-title":"Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse.","volume":"77","author":"Guo","year":"2003","journal-title":"J Virol"},{"issue":"17","key":"2019111814452454000_B13","doi-asserted-by":"crossref","first-page":"9336","DOI":"10.1128\/JVI.78.17.9336-9342.2004","article-title":"Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat.","volume":"78","author":"Guo","year":"2004","journal-title":"J Virol"},{"issue":"36","key":"2019111814452454000_B14","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0408577102","article-title":"Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice.","volume":"102","author":"Chugh","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111814452454000_B15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4161\/cbt.10.10.13291","article-title":"Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice.","volume":"10","author":"Ahmad","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2019111814452454000_B16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI44417","article-title":"Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice.","volume":"121","author":"Ballon","year":"2011","journal-title":"J Clin Invest"},{"issue":"12","key":"2019111814452454000_B17","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood.V94.12.4247","article-title":"Role of vascular endothelial growth factor\/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas.","volume":"94","author":"Aoki","year":"1999","journal-title":"Blood"},{"issue":"8","key":"2019111814452454000_B18","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1182\/blood.V97.8.2526","article-title":"Serum viral interleukin-6 in AIDS-related multicentric Castleman disease.","volume":"97","author":"Aoki","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2019111814452454000_B19","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.V97.7.2173","article-title":"Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders.","volume":"97","author":"Aoki","year":"2001","journal-title":"Blood"},{"issue":"9","key":"2019111814452454000_B20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrclinonc.2010.103","article-title":"Castleman's disease: a two compartment model of HHV-8 infection.","volume":"7","author":"Schulte","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2019111814452454000_B21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/1096-9071(200007)61:3<332::AID-JMV8>3.0.CO;2-3","article-title":"Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion.","volume":"61","author":"Mori","year":"2000","journal-title":"J Med Virol"},{"issue":"2","key":"2019111814452454000_B22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1172\/JCI114749","article-title":"Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.","volume":"86","author":"Brandt","year":"1990","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111814452454000_B23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF01757344","article-title":"Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop.","volume":"69","author":"Burger","year":"1994","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111814452454000_B24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.10794","article-title":"Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.","volume":"92","author":"Kawabata","year":"2007","journal-title":"Haematologica"},{"issue":"23","key":"2019111814452454000_B25","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111814452454000_B26","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease.","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"issue":"9","key":"2019111814452454000_B27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199403033300904","article-title":"Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.","volume":"330","author":"Beck","year":"1994","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111814452454000_B28","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111814452454000_B29","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1128\/JVI.73.10.8268-8278.1999","article-title":"Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6.","volume":"73","author":"Wan","year":"1999","journal-title":"J Virol"},{"issue":"5","key":"2019111814452454000_B30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6.","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"2019111814452454000_B31","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1128\/JVI.01601-08","article-title":"Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor.","volume":"83","author":"Adam","year":"2009","journal-title":"J Virol"},{"issue":"17","key":"2019111814452454000_B32","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1128\/JVI.00420-06","article-title":"Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display.","volume":"80","author":"Kovaleva","year":"2006","journal-title":"J Virol"},{"issue":"9","key":"2019111814452454000_B33","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.4049\/jimmunol.164.9.4672","article-title":"IL-6 receptor independent stimulation of human gp130 by viral IL-6.","volume":"164","author":"Mullberg","year":"2000","journal-title":"J Immunol"},{"issue":"9","key":"2019111814452454000_B34","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling.","volume":"121","author":"Jones","year":"2011","journal-title":"J Clin Invest"},{"issue":"8","key":"2019111814452454000_B35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/dna.1992.11.587","article-title":"Long-term consequences of interleukin-6 overexpression in transgenic mice.","volume":"11","author":"Woodroofe","year":"1992","journal-title":"DNA Cell Biol"},{"issue":"3","key":"2019111814452454000_B36","first-page":"235","article-title":"Regulation of the expression of class I MHC genes.","volume":"10","author":"Singer","year":"1990","journal-title":"Crit Rev Immunol"},{"issue":"6469","key":"2019111814452454000_B37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6-deficient mice.","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"issue":"4","key":"2019111814452454000_B38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1634\/theoncologist.2010-0212","article-title":"Castleman's disease: from basic mechanisms to molecular therapeutics.","volume":"16","author":"El-Osta","year":"2011","journal-title":"Oncologist"},{"issue":"12","key":"2019111814452454000_B39","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/94.12.926","article-title":"Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene.","volume":"94","author":"Prakash","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"2019111814452454000_B40","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/sj.onc.1206407","article-title":"Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK\/AP1 pathways.","volume":"22","author":"An","year":"2003","journal-title":"Oncogene"},{"issue":"5","key":"2019111814452454000_B41","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1128\/JVI.01871-08","article-title":"Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13\/vFLIP in endothelial cells.","volume":"83","author":"Sakakibara","year":"2009","journal-title":"J Virol"},{"issue":"1","key":"2019111814452454000_B42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56","article-title":"Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.","volume":"95","author":"Nishimoto","year":"2000","journal-title":"Blood"},{"issue":"19","key":"2019111814452454000_B43","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.86.19.7547","article-title":"IgG1 plasmacytosis in interleukin 6 transgenic mice.","volume":"86","author":"Suematsu","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111814452454000_B44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1073\/pnas.89.1.232","article-title":"Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.","volume":"89","author":"Suematsu","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111814452454000_B45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2141.1996.6282074.x","article-title":"Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice.","volume":"94","author":"Dedera","year":"1996","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111814452454000_B46","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1084\/jem.185.4.755","article-title":"Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice.","volume":"185","author":"Peters","year":"1997","journal-title":"J Exp Med"},{"issue":"2","key":"2019111814452454000_B47","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9440(10)65605-2","article-title":"Hepatocellular hyperplasia, plasmacytoma formation, and extracellular hematopoiesis in interleukin (IL)-6\/soluble IL-6 receptor double-transgenic mice.","volume":"153","author":"Schirmacher","year":"1998","journal-title":"Am J Pathol"},{"issue":"3","key":"2019111814452454000_B48","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/JVI.05782-11","article-title":"Human herpesvirus 8 viral interleukin-6 interacts with splice variant 2 of vitamin K epoxide reductase complex subunit 1.","volume":"86","author":"Chen","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"2019111814452454000_B49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur J Biochem"},{"issue":"5","key":"2019111814452454000_B50","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14728222.11.5.613","article-title":"The IL-6\/sIL-6R complex as a novel target for therapeutic approaches.","volume":"11","author":"Rose-John","year":"2007","journal-title":"Expert Opin Ther Targets"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/22\/5173\/1492994\/zh802212005173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/22\/5173\/1492994\/zh802212005173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T17:14:06Z","timestamp":1593969246000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/22\/5173\/105512\/HHV8encoded-viral-IL6-collaborates-with-mouse-IL6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,31]]},"references-count":50,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2012,5,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-09-377705","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,31]]}}}